Abeona Therapeutics Inc (NASDAQ:ABEO) gets downgraded to Neutral by Mizuho

ME Staff
-
0

Analyst Ratings For Abeona Therapeutics Inc (NASDAQ:ABEO)

Today, Abeona Therapeutics Inc (NASDAQ:ABEO) stock was downgraded by Mizuho from Buy to Neutral.

There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Abeona Therapeutics Inc (NASDAQ:ABEO) is Buy with a consensus target price of $24.60 per share, a potential 693.55% upside.

Some recent analyst ratings include

  • 7/26/2019-Abeona Therapeutics Inc (NASDAQ:ABEO) gets downgraded to Neutral by Mizuho
  • 5/14/2019-Abeona Therapeutics Inc (NASDAQ:ABEO) had its Buy rating reiterated by Cantor Fitzgerald with a $29.00 price target
  • 5/1/2019-Abeona Therapeutics Inc (NASDAQ:ABEO) had its Buy rating reiterated by Maxim Group
  • 6/27/2018-Abeona Therapeutics Inc (NASDAQ:ABEO) has coverage initiated with a Buy rating and $26.00 price target
  • 6/5/2018-Abeona Therapeutics Inc (NASDAQ:ABEO) has coverage initiated with a Buy rating and $29.00 price target
  • On 4/11/2019 Stefano Buono, Director, bought 70,000 with an average share price of $7.80 per share and the total transaction amounting to $546,000.00.
  • On 4/8/2019 Stephen B. Howell, Director, bought 4,000 with an average share price of $7.77 per share and the total transaction amounting to $31,080.00.
  • On 9/20/2016 Todd Wider, Director, bought 5,000 with an average share price of $5.48 per share and the total transaction amounting to $27,400.00.
  • On 7/31/2015 Mark J Ahn, Director, bought 18,182 with an average share price of $5.50 per share and the total transaction amounting to $100,001.00.
  • On 1/26/2015 Mark J Ahn, Director, bought 25,000 with an average share price of $4.00 per share and the total transaction amounting to $100,000.00.
  • On 12/24/2014 Steven H Rouhandeh, Director, bought 250,000 with an average share price of $4.00 per share and the total transaction amounting to $1,000,000.00.

About Abeona Therapeutics Inc (NASDAQ:ABEO)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. Read More…

Recent Trading Activity for Abeona Therapeutics Inc (NASDAQ:ABEO)
Shares of Abeona Therapeutics Inc closed the previous trading session at 3.10 −0.15 4.77% with shares trading hands.